Kymab

About:

Kymab is a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics.

Twitter/X: kymabltd

Top Investors: Wellcome Trust, Bill & Melinda Gates Foundation, Malin Corporation, Woodford Investment Management, ORI Capital

Description:

Kymab is a clinical-stage biopharmaceutical company developing fully human monoclonal antibody therapeutics with a focus on immune-mediated diseases and immuno-oncology using its proprietary, integrated platforms collectively called IntelliSelect®. Kymab’s IntelliSelect Transgenic platforms contain a full diversity of human antibodies, making them the most comprehensive antibody platforms available. The company was founded in 2010 and is based in Cambridge, the United Kingdom.

Total Funding Amount:

$229M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Cambridge, Cambridgeshire, United Kingdom

Founded Date:

2010-01-01

Contact Email:

info(AT)kymab.com

Founders:

Allan Bradley, Glenn Friedrich

Number of Employees:

101-250

Last Funding Date:

2017-01-10

IPO Status:

Private

Industries: